Marked Reduction in 28-day Mortality Among Elderly Patients with Severe Community-acquired Pneumonia: Post Hoc Analysis of a Large Randomized Controlled Trial

Yan Liu,1,* Chi Zhang,2,* Chengyu Li,1 Chunxue Bai,3 Hongcai Shang1 1Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 2Institute for Brain Disorders, Dongzhime...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Liu Y, Zhang C, Li C, Bai C, Shang H
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	severe community-acquired pneumonia randomized controlled trial post hoc analysis 28-day mortality rate xuebijing injection Geriatrics RC952-954.6
Acceso en línea:	https://doaj.org/article/acc7c661d1424f45a49f6f265bde8d7b
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:acc7c661d1424f45a49f6f265bde8d7b
record_format	dspace
spelling	oai:doaj.org-article:acc7c661d1424f45a49f6f265bde8d7b2021-12-02T11:38:05ZMarked Reduction in 28-day Mortality Among Elderly Patients with Severe Community-acquired Pneumonia: Post Hoc Analysis of a Large Randomized Controlled Trial1178-1998https://doaj.org/article/acc7c661d1424f45a49f6f265bde8d7b2020-11-01T00:00:00Zhttps://www.dovepress.com/marked-reduction-in-28-day-mortality-among-elderly-patients-with-sever-peer-reviewed-article-CIAhttps://doaj.org/toc/1178-1998Yan Liu,1,* Chi Zhang,2,* Chengyu Li,1 Chunxue Bai,3 Hongcai Shang1 1Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 2Institute for Brain Disorders, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 3Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hongcai ShangKey Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, 5 Haiyuncang, Dongcheng District, Beijing 100700, People’s Republic of ChinaEmail shanghongcai@126.comBackground: There were few studies on the case mortality of severe community-acquired pneumonia (CAP) in elderly people. Improved outcomes with XueBiJing (XBJ) injection vs placebo have been shown in overall trial populations. We investigated the efficacy and safety of XBJ vs placebo in subjects with severe CAP stratified by age (< 65 and ≥ 65 years).Methods: This post hoc analysis of a large randomized trial compared data from elderly and nonelderly patients with XBJ, 100 mL, q 12 h, or a visually indistinguishable placebo for five-to-seven days.Results: Among subjects ≥ 65 years (n=291), 23 (16.0%) XBJ recipients and 41 (27.9%) placebo recipients (P=0.014) died within 28 days. Among subjects < 65 years (n=360), XBJ still had lower mortality (XBJ 15.6% vs placebo 22.8%; P=0.082), without significantly statistical difference. Total duration of ICU stay and the time of mechanical ventilation were similar in both groups (P> 0.05). XBJ also had a favorable safety profile, with no clinically relevant differences between the two groups. The overall incidence of adverse events was similar in both groups.Conclusion: XBJ was safe and effective for reduction in 28-day mortality among elderly patients with severe CAP. Additional confirmatory trials involving elderly patients are needed to further confirm the present results.Trial Registration: http://www.chictr.org.cn/index.aspx. ChiCTR-TRC-13003534.Keywords: severe community-acquired pneumonia, randomized controlled trial, post hoc analysis, 28-day mortality rate, XueBiJing injectionLiu YZhang CLi CBai CShang HDove Medical Pressarticlesevere community-acquired pneumoniarandomized controlled trialpost hoc analysis28-day mortality ratexuebijing injectionGeriatricsRC952-954.6ENClinical Interventions in Aging, Vol Volume 15, Pp 2109-2115 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	severe community-acquired pneumonia randomized controlled trial post hoc analysis 28-day mortality rate xuebijing injection Geriatrics RC952-954.6
spellingShingle	severe community-acquired pneumonia randomized controlled trial post hoc analysis 28-day mortality rate xuebijing injection Geriatrics RC952-954.6 Liu Y Zhang C Li C Bai C Shang H Marked Reduction in 28-day Mortality Among Elderly Patients with Severe Community-acquired Pneumonia: Post Hoc Analysis of a Large Randomized Controlled Trial
description	Yan Liu,1,* Chi Zhang,2,* Chengyu Li,1 Chunxue Bai,3 Hongcai Shang1 1Key Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 2Institute for Brain Disorders, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, People’s Republic of China; 3Department of Respiratory Medicine, Zhongshan Hospital, Fudan University, Shanghai, People’s Republic of China*These authors contributed equally to this workCorrespondence: Hongcai ShangKey Laboratory of Chinese Internal Medicine of Ministry of Education and Beijing, Dongzhimen Hospital, Beijing University of Chinese Medicine, 5 Haiyuncang, Dongcheng District, Beijing 100700, People’s Republic of ChinaEmail shanghongcai@126.comBackground: There were few studies on the case mortality of severe community-acquired pneumonia (CAP) in elderly people. Improved outcomes with XueBiJing (XBJ) injection vs placebo have been shown in overall trial populations. We investigated the efficacy and safety of XBJ vs placebo in subjects with severe CAP stratified by age (< 65 and ≥ 65 years).Methods: This post hoc analysis of a large randomized trial compared data from elderly and nonelderly patients with XBJ, 100 mL, q 12 h, or a visually indistinguishable placebo for five-to-seven days.Results: Among subjects ≥ 65 years (n=291), 23 (16.0%) XBJ recipients and 41 (27.9%) placebo recipients (P=0.014) died within 28 days. Among subjects < 65 years (n=360), XBJ still had lower mortality (XBJ 15.6% vs placebo 22.8%; P=0.082), without significantly statistical difference. Total duration of ICU stay and the time of mechanical ventilation were similar in both groups (P> 0.05). XBJ also had a favorable safety profile, with no clinically relevant differences between the two groups. The overall incidence of adverse events was similar in both groups.Conclusion: XBJ was safe and effective for reduction in 28-day mortality among elderly patients with severe CAP. Additional confirmatory trials involving elderly patients are needed to further confirm the present results.Trial Registration: http://www.chictr.org.cn/index.aspx. ChiCTR-TRC-13003534.Keywords: severe community-acquired pneumonia, randomized controlled trial, post hoc analysis, 28-day mortality rate, XueBiJing injection
format	article
author	Liu Y Zhang C Li C Bai C Shang H
author_facet	Liu Y Zhang C Li C Bai C Shang H
author_sort	Liu Y
title	Marked Reduction in 28-day Mortality Among Elderly Patients with Severe Community-acquired Pneumonia: Post Hoc Analysis of a Large Randomized Controlled Trial
title_short	Marked Reduction in 28-day Mortality Among Elderly Patients with Severe Community-acquired Pneumonia: Post Hoc Analysis of a Large Randomized Controlled Trial
title_full	Marked Reduction in 28-day Mortality Among Elderly Patients with Severe Community-acquired Pneumonia: Post Hoc Analysis of a Large Randomized Controlled Trial
title_fullStr	Marked Reduction in 28-day Mortality Among Elderly Patients with Severe Community-acquired Pneumonia: Post Hoc Analysis of a Large Randomized Controlled Trial
title_full_unstemmed	Marked Reduction in 28-day Mortality Among Elderly Patients with Severe Community-acquired Pneumonia: Post Hoc Analysis of a Large Randomized Controlled Trial
title_sort	marked reduction in 28-day mortality among elderly patients with severe community-acquired pneumonia: post hoc analysis of a large randomized controlled trial
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/acc7c661d1424f45a49f6f265bde8d7b
work_keys_str_mv	AT liuy markedreductionin28daymortalityamongelderlypatientswithseverecommunityacquiredpneumoniaposthocanalysisofalargerandomizedcontrolledtrial AT zhangc markedreductionin28daymortalityamongelderlypatientswithseverecommunityacquiredpneumoniaposthocanalysisofalargerandomizedcontrolledtrial AT lic markedreductionin28daymortalityamongelderlypatientswithseverecommunityacquiredpneumoniaposthocanalysisofalargerandomizedcontrolledtrial AT baic markedreductionin28daymortalityamongelderlypatientswithseverecommunityacquiredpneumoniaposthocanalysisofalargerandomizedcontrolledtrial AT shangh markedreductionin28daymortalityamongelderlypatientswithseverecommunityacquiredpneumoniaposthocanalysisofalargerandomizedcontrolledtrial
_version_	1718395780388093952

Marked Reduction in 28-day Mortality Among Elderly Patients with Severe Community-acquired Pneumonia: Post Hoc Analysis of a Large Randomized Controlled Trial

Ejemplares similares